Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | LIPE | Q05469 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905594 | 0.88 | TRPM8 (0.42) | TRPM8LMNA | |
| SCHEMBL4903605 | 0.84 | TRPM8 (0.47) | TRPM8 | |
| SCHEMBL4907195 | 0.82 | LMNA (0.39) | TRPM8LMNA | |
| SCHEMBL4905533 | 0.81 | KDM4E (0.42) | TRPM8 | |
| SCHEMBL4899415 | 0.81 | MEN1 (0.41) | TRPM8LMNA | |
| SCHEMBL4904293 | 0.81 | LMNA (0.45) | TRPM8LMNA | |
| SCHEMBL4901463 | 0.81 | ALDH1A1 (0.44) | TRPM8RAB9ALMNA | |
| SCHEMBL4894397 | 0.80 | MEN1 (0.49) | TRPM8LMNA | |
| SCHEMBL4902365 | 0.80 | IDO1 (0.42) | DAGLASCN9ALIPEIDO1RAB9A | |
| SCHEMBL4904348 | 0.80 | LMNA (0.47) | TRPM8RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | DAGLA 831/4885ABHD6 709/4885SCN9A 4504/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | DAGLA 831/4885ABHD6 709/4885SCN9A 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.